Navigation Links
OHSU research team joins elite consortium dedicated to curing type 1 diabetes
Date:9/15/2010

PORTLAND, Ore. -- Oregon Health & Science University's Markus Grompe, M.D., will lead a multi-center team of scientists selected to participate in the prestigious Beta Cell Biology Consortium (BCBC). Funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the consortium's long-term goal is to develop a cell-based therapy for insulin delivery in type 1 diabetes patients.

"The goal of our work is to produce abundant quantities of functional human insulin-producing beta cells that can be used for transplantation to cure patients with type 1 diabetes. Our group in particular is focused on novel sources for transplantable beta cell replacements," said Grompe, principal investigator and director of the Pap Family Pediatric Research Institute, OHSU Doernbecher Children's Hospital; and director of the Oregon Stem Cell Center at OHSU.

Type 1 diabetes, formerly called juvenile diabetes, is characterized by a lack of insulin that results from the destruction of the insulin-producing beta cells of the pancreas. Without insulin, the body cannot process the glucose it receives from food and requires for energy. People with type 1 diabetes must take insulin every day, either by injection or continuously through a pump. To ensure they are receiving the proper amount, they frequently test their blood-glucose levels, which requires multiple finger pricks throughout the day.

"It is our hope that through the work of this interactive consortium, we can eliminate the need for this painful, lifelong ritual," said Grompe.

Grompe is a nationally accomplished stem cell and gene therapy expert. His pioneering work on liver stem cells and liver regeneration medicine provided a natural segue to this line of research. Recent studies by Grompe, BCBC project co-investigator Philip Streeter, Ph.D., and others indicate adult liver cells can successfully be converted into insulin-producing beta cells through genetic reprogramming in a mouse model. However, it is not yet know which liver cells can best be transformed into beta cells, and existing methods for growing liver cells in tissue culture are not well developed, according to Grompe.

With the support of this and similar grants, Grompe and colleagues are working to determine which type of liver cell is most easily converted and perfecting their methods of growing them in tissue culture. In addition, they are exploring the potential for harvesting and manipulating cells from novel sources, including the gall bladder.

"We have found that human gall bladder cells, which are very similar to the cells within the liver, can be grown and expanded in tissue culture very easily. It is a very promising source of reprogrammable beta cells," explained Grompe, who also is a professor of pediatrics and molecular and medical genetics in the OHSU School of Medicine, OHSU Doernbecher Children's Hospital.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... ... Borers kill Ash trees in as little as 1-3 years. The signs of ... Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in Northeast ... of decline from Emerald Ash Borers, two Ash trees continue to thrive. , ...
(Date:9/24/2017)... ... ... Bhowanie Benimadhu’s new book “ Our Creative World: Our Created Life on ... in both Eastern and Western religious traditions and spirituality such as Hinduism ... humankind for the past thousands of years and still are,” Benimadhu says. “By seeking ...
(Date:9/24/2017)... BWI (PRWEB) , ... September 25, 2017 , ... The ... resort is re-opening on October 1st. And, throughout the month of October, the ... rentals. , Hurricane Irma and Maria have passed and damage to the Venetian ...
(Date:9/24/2017)... Turks & Caicos Islands, BWI (PRWEB) , ... September 24, 2017 ... ... Islands, the #1 rated resort on TripAdvisor and one of Provo's premier boutique resorts, ... no reported structural damage to the resort after devastating Hurricanes Irma and more recently ...
(Date:9/24/2017)... ... ... “The Messiah 8 with the 3rd Anti Christ”: a forceful and dynamic narrative ... 3rd Anti Christ” is the creation of published author, Albert Velazquez. , ... life,” Velazquez states, “I always come to the same conclusion: God loves working in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
Breaking Medicine Technology: